{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,21]],"date-time":"2026-01-21T04:48:59Z","timestamp":1768970939890,"version":"3.49.0"},"reference-count":22,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:00:00Z","timestamp":1553126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T00:00:00Z","timestamp":1553126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BioDrugs"],"published-print":{"date-parts":[[2019,4,11]]},"DOI":"10.1007\/s40259-019-00343-8","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T08:18:01Z","timestamp":1553156281000},"page":"207-220","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["PF-06881893 (Nivestym\u2122), a Filgrastim Biosimilar, Versus US-Licensed Filgrastim Reference Product (US-Neupogen\u00ae): Pharmacokinetics, Pharmacodynamics, Immunogenicity, and Safety of Single or Multiple Subcutaneous Doses in Healthy Volunteers"],"prefix":"10.1007","volume":"33","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1652-2749","authenticated-orcid":false,"given":"Hsuan-Ming","family":"Yao","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Faith D.","family":"Ottery","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Troy","family":"Borema","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stuart","family":"Harris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Levy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tom B.","family":"May","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Shahrzad","family":"Moosavi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jeffrey","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martin","family":"Summers","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,3,21]]},"reference":[{"issue":"6","key":"343_CR1","doi-asserted-by":"publisher","first-page":"351","DOI":"10.1158\/2326-6066.CIR-13-0151","volume":"1","author":"D Metcalf","year":"2013","unstructured":"Metcalf D. The colony-stimulating factors and cancer. Cancer Immunol Res. 2013;1(6):351\u20136.","journal-title":"Cancer Immunol Res."},{"key":"343_CR2","unstructured":"Amgen Inc. Neupogen (filgrastim) US prescribing information. 2018. http:\/\/pi.amgen.com\/united_states\/neupogen\/neupogen_pi_hcp_english.pdf. Accessed 17 Aug 2018."},{"key":"343_CR3","unstructured":"Amgen Ltd. Neupogen (filgrastim) 30MU and 48MU solution for injection: summary of product characteristics. 2018. https:\/\/www.medicines.org.uk\/emc\/search?q=neupogen. Accessed 26 Sept 2018."},{"key":"343_CR4","unstructured":"Hospira Inc. Nivestym (filgrastim-aafi) US prescribing information. 2018. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761080s000lbl.pdf. Accessed 17 Aug 2018."},{"key":"343_CR5","unstructured":"US Food and Drug Administration. Scientific Considerations in Demonstrating Biosimilarity to a Reference Product. Guidance for Industry. 2015. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM291128.pdf. Accessed 9 May 2018."},{"key":"343_CR6","unstructured":"Przepiorka D. Cross-discipline team leader review: BLA 761080 Nivestym (filgrastim-aafi). 2018. https:\/\/www.fda.gov\/downloads\/Drugs\/DevelopmentApprovalProcess\/DevelopmentResources\/UCM617299.pdf. Accessed 28 Aug 2018."},{"key":"343_CR7","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.exphem.2016.10.008","volume":"46","author":"P Dwivedi","year":"2017","unstructured":"Dwivedi P, Greis KD. Granulocyte colony-stimulating factor receptor signaling in severe congenital neutropenia, chronic neutrophilic leukemia, and related malignancies. Exp Hematol. 2017;46:9\u201320.","journal-title":"Exp Hematol."},{"key":"343_CR8","unstructured":"US Food and Drug Administration. Clinical pharmacology data to support a demonstration of biosimilarity to a reference product. Guidance for industry. 2016. http:\/\/www.fda.gov\/downloads\/Drugs\/GuidanceComplianceRegulatoryInformation\/Guidances\/UCM397017.pdf. Accessed 9 May 2018."},{"key":"343_CR9","unstructured":"US Food and Drug Administration. Assay development and validation for immunogenicity testing of therapeutic protein products (draft guidance). 2016. http:\/\/www.nihs.go.jp\/dbcb\/immunogenicity\/FDA_2016_Assay%20Development%20and%20Validation%20for%20Immunogenicity%20Testing%20of%20Therapeutic%20Protein%20Products.pdf. Accessed 8 May 2018."},{"issue":"5","key":"343_CR10","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1016\/j.jpba.2008.09.020","volume":"48","author":"G Shankar","year":"2008","unstructured":"Shankar G, Devanarayan V, Amaravadi L, Barrett YC, Bowsher R, Finco-Kent D, et al. Recommendations for the validation of immunoassays used for detection of host antibodies against biotechnology products. J Pharm Biomed Anal. 2008;48(5):1267\u201381.","journal-title":"J Pharm Biomed Anal."},{"key":"343_CR11","unstructured":"US Food and Drug Administration. Assay development for immunogenicity testing of therapeutic proteins (draft guidance). 2009. https:\/\/www.fdanews.com\/ext\/resources\/files\/archives\/8\/8495dft12_09.pdf. Accessed 8 May 2018."},{"key":"343_CR12","unstructured":"US Food and Drug Administration. Immunogenicity Assessment for Therapeutic Protein Products. Guidance for Industry. 2014. https:\/\/www.fda.gov\/ucm\/groups\/fdagov-public\/@fdagov-drugs-gen\/documents\/document\/ucm338856.pdf. Accessed 8 May 2018."},{"key":"343_CR13","unstructured":"Hospira UK Ltd. Nivestim (filgrastim) 12 MU\/0.2\u00a0ml, 30 MU\/0.5\u00a0ml and 48MU\/0.5\u00a0ml solution for injection\/infusion: summary of product characteristics. 2018. https:\/\/www.medicines.org.uk\/emc\/product\/575\/smpc. Accessed 26 Sept 2018."},{"issue":"4","key":"343_CR14","doi-asserted-by":"publisher","first-page":"1202","DOI":"10.1111\/j.0006-341X.1999.01202.x","volume":"55","author":"IS Chan","year":"1999","unstructured":"Chan IS, Zhang Z. Test-based exact confidence intervals for the difference of two binomial proportions. Biometrics. 1999;55(4):1202\u20139.","journal-title":"Biometrics."},{"issue":"4","key":"343_CR15","doi-asserted-by":"publisher","first-page":"319","DOI":"10.1007\/s40259-018-0287-0","volume":"32","author":"FX Frapaise","year":"2018","unstructured":"Frapaise FX. The end of phase 3 Clinical trials in biosimilars development? BioDrugs. 2018;32(4):319\u201324.","journal-title":"BioDrugs."},{"issue":"4","key":"343_CR16","doi-asserted-by":"publisher","first-page":"722","DOI":"10.1016\/S0149-2918(98)80135-5","volume":"20","author":"JC Borleffs","year":"1998","unstructured":"Borleffs JC, Bosschaert M, Vrehen HM, Schneider MM, van Strijp J, Small MK, et al. Effect of escalating doses of recombinant human granulocyte colony-stimulating factor (filgrastim) on circulating neutrophils in healthy subjects. Clin Ther. 1998;20(4):722\u201336.","journal-title":"Clin Ther."},{"issue":"4","key":"343_CR17","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/ajh.1052","volume":"66","author":"P van Der Auwera","year":"2001","unstructured":"van Der Auwera P, Platzer E, Xu ZX, Schulz R, Feugeas O, Capdeville R, et al. Pharmacodynamics and pharmacokinetics of single doses of subcutaneous pegylated human G-CSF mutant (Ro 25-8315) in healthy volunteers: comparison with single and multiple daily doses of filgrastim. Am J Hematol. 2001;66(4):245\u201351.","journal-title":"Am J Hematol."},{"issue":"7","key":"343_CR18","doi-asserted-by":"publisher","first-page":"1419","DOI":"10.1093\/annonc\/mdp574","volume":"21","author":"P Gascon","year":"2010","unstructured":"Gascon P, Fuhr U, Sorgel F, Kinzig-Schippers M, Makhson A, Balser S, et al. Development of a new G-CSF product based on biosimilarity assessment. Ann Oncol. 2010;21(7):1419\u201329.","journal-title":"Ann Oncol."},{"issue":"1","key":"343_CR19","doi-asserted-by":"publisher","first-page":"43","DOI":"10.2165\/00063030-200923010-00005","volume":"23","author":"H Lubenau","year":"2009","unstructured":"Lubenau H, Bias P, Maly AK, Siegler KE, Mehltretter K. Pharmacokinetic and pharmacodynamic profile of new biosimilar filgrastim XM02 equivalent to marketed filgrastim Neupogen: single-blind, randomized, crossover trial. BioDrugs. 2009;23(1):43\u201351.","journal-title":"BioDrugs."},{"issue":"1","key":"343_CR20","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1002\/cyto.b.20611","volume":"82","author":"L Eidenschink","year":"2012","unstructured":"Eidenschink L, DiZerega G, Rodgers K, Bartlett M, Wells DA, Loken MR. Basal levels of CD34 positive cells in peripheral blood differ between individuals and are stable for 18 months. Cytom B Clin Cytom. 2012;82(1):18\u201325.","journal-title":"Cytom B Clin Cytom."},{"issue":"12","key":"343_CR21","doi-asserted-by":"crossref","first-page":"4437","DOI":"10.1182\/blood.V86.12.4437.bloodjournal86124437","volume":"86","author":"AP Grigg","year":"1995","unstructured":"Grigg AP, Roberts AW, Raunow H, Houghton S, Layton JE, Boyd AW, et al. Optimizing dose and scheduling of filgrastim (granulocyte colony-stimulating factor) for mobilization and collection of peripheral blood progenitor cells in normal volunteers. Blood. 1995;86(12):4437\u201345.","journal-title":"Blood."},{"issue":"7","key":"343_CR22","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1046\/j.1537-2995.1996.36796323059.x","volume":"36","author":"DF Stroncek","year":"1996","unstructured":"Stroncek DF, Clay ME, Petzoldt ML, Smith J, Jaszcz W, Oldham FB, et al. Treatment of normal individuals with granulocyte-colony-stimulating factor: donor experiences and the effects on peripheral blood CD34+\u2009cell counts and on the collection of peripheral blood stem cells. Transfusion. 1996;36(7):601\u201310.","journal-title":"Transfusion."}],"container-title":["BioDrugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-019-00343-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40259-019-00343-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40259-019-00343-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,10]],"date-time":"2021-08-10T17:32:21Z","timestamp":1628616741000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40259-019-00343-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,3,21]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2019,4,11]]}},"alternative-id":["343"],"URL":"https:\/\/doi.org\/10.1007\/s40259-019-00343-8","relation":{},"ISSN":["1173-8804","1179-190X"],"issn-type":[{"value":"1173-8804","type":"print"},{"value":"1179-190X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,3,21]]},"assertion":[{"value":"21 March 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"This work was funded by Hospira Inc, which was acquired by Pfizer Inc in September 2015, and by Pfizer Inc. Open access publication of this article was funded by Pfizer Inc.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"TBM, SM, MS, H-MY, and JZ are employees of and own stock or options in Pfizer Inc. FDO was an employee of and held stock or options in Pfizer Inc at the time of study conduct. TB, SH, and JL are employees of Quotient Sciences, formerly Seaview Research Inc., which received funding from Pfizer Inc to perform the studies described in the manuscript.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The protocol and all amendments for each study were approved by the institutional review board at each of the investigational centers participating in the studies. All studies were conducted in compliance with the protocol, International Conference on Harmonization guidelines, all applicable regulatory requirements, and the Declaration of Helsinki. Subjects provided written informed consent prior to the performance of any study-specific procedures. Volunteers were free to withdraw from the study at any time.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval and informed consent"}},{"value":"Upon request, and subject to certain criteria, conditions and exceptions (see  for more information), Pfizer will provide access to individual de-identified\u00a0participant data from Pfizer-sponsored global interventional clinical studies conducted for medicines, vaccines, and medical devices (1) for indications that have been approved in the USA and\/or EU or\u00a0(2) in programs that have been terminated (i.e., development for all indications has been discontinued).\u00a0Pfizer will also consider requests for the protocol, data dictionary, and statistical analysis plan. Data may be requested from Pfizer trials 24\u00a0months after study completion. The de-identified\u00a0participant data will be made available to researchers whose proposals meet the research criteria and other conditions, and for which an exception does not apply, via a secure portal. To gain access, data requestors must enter into a data access agreement with Pfizer.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Data availability"}}]}}